MBOT Microbot Medical, Inc. Loading... : Investor Sentiment and Bull/Bear Views

Loading chart...
Top Calls

No data yet

Price change since each call, adjusted for long/short direction. Results calculated:

Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
All Content
Source feeds
Buzzberg Top 50
All market capsNo capitalization filter
200 B and aboveMega
10 B to 200 BLarge
2 B to 10 BMid
0 to 2 BSmall
Custom
Enter market cap range in B USD
All directions
▲ Long
▼ Short
⛔ Avoid
✂ Close
◦ Others
Any score
LOW+
MED+
HIGH
? ?
23:37
Jun 28
u/IndividualNo7155 Reddit r/smallstreetbets
MBOT pump based on stale SI data
The author warns that MBOT is being pumped by bots using outdated Fintel short interest data, and that a big dilution has occurred with the real short interest around 12% per Finviz. The implication is that the squeeze narrative is false and buyers risk losing money. The author explicitly says not to waste time and money on it. Main risk is that the dilution/SI data interpretation could be wrong.
MBOT
HIGH
22:16
Jan 18
u/No_Lack_3904 Reddit r/smallstreetbets
MBOT release better than expected
The author argues Microbot Medical's Limited Market Release is progressing better than expected, and calculates 17.5M USD in revenue from 5000 units at 3500 USD each, calling it huge. The implied catalyst is the ongoing commercial rollout of the product. No specific risk is stated.
MBOT 1ST
MED
14:57
Jan 13
u/Southern_Two_8108 Reddit r/pennystocks
Long MBOT on FDA-cleared LIBERTY commercialization and Q2 2026 launch
Author claims Microbot Medical is the most undervalued, overlooked multi-bagger, citing its FDA-cleared LIBERTY endovascular robotic system that has entered limited release with healthcare providers. The mechanism is commercialization: FDA 510(k) clearance unlocks U.S. sales, early hospital adoption builds pipeline, and a non-dilutive grant supports manufacturing without shareholder dilution. Catalysts include full market release of LIBERTY in Q2 2026, expansion into more hospitals and procedure types, strategic partnerships, teleintervention trials, and a targeted 2.5 million annual U.S. peripheral endovascular procedures.
MBOT 1ST
HIGH

About MBOT Investor Commentary

Across the available history and selected sources, Buzzberg tracks MBOT (Microbot Medical, Inc.) across 2 sources: 2 bullish vs 0 bearish calls from 3 authors. Historical directional balance: 67% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 3 total trade ideas tracked. Latest voices: u/IndividualNo7155, u/No_Lack_3904, u/Southern_Two_8108.